Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides

Ndayishimiye, John; Popat, Amirali; Blaskovich, Mark A.T.; Falconer, James R.

doi:10.1016/j.jconrel.2020.05.002

Cited by 24 publications

(16 citation statements)

References 267 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many nanotechnology-based cosmeceutical products capturing the market and potential of products for AD is being proven at the research level. However, there are several emerging nanocarriers such as ionic liquids (103), silica nanoparticles (104), plant-and milk-based proteins, and silicon nanoparticles (105), which are already explored for oral delivery and holds enormous potential for topical delivery of peptides, proteins, and poorly soluble and permeable small molecules (106). Their untapped potential needs to be investigated in detail.…”

Section: Discussionmentioning

confidence: 99%

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Globally, the prevalence of Atopic dermatitis (AD) is significantly increasing and affecting around 20% of population including children. Complex interactions amongst abnormality in epidermal barrier function, environment, infectious agents and immunological defects are considered as key factors in the pathogenesis of AD. Although the role of oxidative stress has been studied in some skin diseases, investigation of the same in AD is intermittent. Calcineurin inhibitors and/or topical corticosteroids are currently available; however, it causes atrophy of the skin, burning sensation, and systemic side effects which leads to poor patient compliance. These limitations provoke the strong need to develop an innovative approach in managing AD. Nanomaterials for effective drug delivery to skin conditions such as AD have attracted a lot of attention owing to its ability to encapsulate, protect, and release the cargo at the diseased skin site. However, there are lots of unmet challenges especially in terms of development of non-toxic formulations and clinical translation of established nanomedicines in the form of accessible products. Numerous formulations have emerged as carrier for poorly soluble and permeable drugs, viz., lipidic, polymeric, metal, silica, liposomes, hydrocarbon gels and this field is evolving. This review is intended to provide an insight incidences associated with pathophysiology of AD and challenges with existing treatments of AD. Focus is kept on reviewing current development and emerging nanomedicines for effective treatment of AD. The review also inculcates merits of several nanomedicines in overcoming challenges of existing products and its future implications.

show abstract

Section: Discussionmentioning

confidence: 99%

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, various hydrolytic and metabolic enzymes also cause oxidation, de-amidation, as well as acid-or base-catalyzed hydrolysis 342 . When MDPs enter the small intestine, they need to penetrate the mucus layer to reach intestinal epithelial cells, and then must be well transported by epithelial cells to avoid enterocyte-based efflux or metabolism 340 , 343 , 344 . Therefore, strategies need to be developed to improve the oral bioavailability of AMPs and their mimics.…”

Section: Mdps-based Formulations and Their Applicationsmentioning

confidence: 99%

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era

Lin

Chi

Yan

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Membrane-disruptive peptides/peptidomimetics (MDPs) are antimicrobials or anticarcinogens that present a general killing mechanism through the physical disruption of cell membranes, in contrast to conventional chemotherapeutic drugs, which act on precise targets such as DNA or specific enzymes. Owing to their rapid action, broad-spectrum activity, and mechanisms of action that potentially hinder the development of resistance, MDPs have been increasingly considered as future therapeutics in the drug-resistant era. Recently, growing experimental evidence has demonstrated that MDPs can also be utilized as adjuvants to enhance the therapeutic effects of other agents. In this review, we evaluate the literature around the broad-spectrum antimicrobial properties and anticancer activity of MDPs, and summarize the current development and mechanisms of MDPs alone or in combination with other agents. Notably, this review highlights recent advances in the design of various MDP-based drug delivery systems that can improve the therapeutic effect of MDPs, minimize side effects, and promote the co-delivery of multiple chemotherapeutics, for more efficient antimicrobial and anticancer therapy.

show abstract

“…Hence, designing a suitable drug delivery system to remedy the shortcomings impeding traditional antibiotics might be an effective and practical method to recover therapeutic activity. Despite their promise for the treatment of sepsis and other infectious diseases, most antimicrobial peptides (AMPs) are still limited by their poor pharmaceutical properties, such as poor solubility and short half-life [ 210 ]. Clavanins, a type of AMP isolated from marine animals, could be formulated with a methacrylate nanocarrier consisting of EUDRAGIT®L 100–55 and RS 30 D solution (3:1 w/w) [ 211 ].…”

Section: Nanotherapeutic Platforms For Sepsis Treatment Through Targementioning

confidence: 99%

“…Despite their capacity to avoid drug resistance, AMPs, especially nonnatural AMPs, show potent cytotoxicity that limits their clinical applications [ 210 – 214 ]. Host defense peptides (HDPs), a class of endogenous AMPs with broad-spectrum activity and favorable biocompatibility, can be identified as a library of lead compounds to develop next-generation antimicrobials for the treatment of infectious diseases such as sepsis [ 215 , 216 ].…”

Section: Nanotherapeutic Platforms For Sepsis Treatment Through Targementioning

confidence: 99%

Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis

et al. 2021

View full text Add to dashboard Cite

Sepsis, a highly life-threatening organ dysfunction caused by uncontrollable immune responses to infection, is a leading contributor to mortality in intensive care units. Sepsis-related deaths have been reported to account for 19.7% of all global deaths. However, no effective and specific therapeutic for clinical sepsis management is available due to the complex pathogenesis. Concurrently eliminating infections and restoring immune homeostasis are regarded as the core strategies to manage sepsis. Sophisticated nanoplatforms guided by supramolecular and medicinal chemistry, targeting infection and/or imbalanced immune responses, have emerged as potent tools to combat sepsis by supporting more accurate diagnosis and precision treatment. Nanoplatforms can overcome the barriers faced by clinical strategies, including delayed diagnosis, drug resistance and incapacity to manage immune disorders. Here, we present a comprehensive review highlighting the pathogenetic characteristics of sepsis and future therapeutic concepts, summarizing the progress of these well-designed nanoplatforms in sepsis management and discussing the ongoing challenges and perspectives regarding future potential therapies. Based on these state-of-the-art studies, this review will advance multidisciplinary collaboration and drive clinical translation to remedy sepsis."Image missing"

show abstract

Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides

Cited by 24 publications

References 267 publications

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era

Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis

Contact Info

Product

Resources

About